NYSE:ZTSPharmaceuticals
Zoetis (ZTS) Launches New Pet Pain Treatments As Valuation Questions Return
Zoetis (ZTS) is back in focus after launching Portela for cats and Lenivia for dogs in Canada and the EU, extending its osteoarthritis pain portfolio with long acting monoclonal antibody therapies.
See our latest analysis for Zoetis.
Despite the new Portela and Lenivia launches, Zoetis shares have been under pressure, with the 90 day share price return down 36.19% and the 1 year total shareholder return down 50.27%, pointing to fading momentum as investors reassess growth prospects and...